| US breast cancer decrease tied to drop in hormone replacement ...
A startling decrease in US breast cancer rates in 2003 may be attributable to the fact that millions of older women stopped using hormone replacement therapy (HRT) in 2002, according to researchers at the University of Texas M.D. Anderson Cancer Center. Investigators reported a remarkable 7 percent relative decline in breast cancer incidence between 2002 and 2003, with a steeper decline of 12 percent in women between the ages of 50 and 69 diagnosed with estrogen receptor positive breast cancer, that is, breast cancer that is hormone-dependent for tumor growth. The findings were presented at the 29th annual San Antonio Breast Cancer Symposium. It is the largest single drop in breast cancer incidence within a single year I am aware of, said Dr. Peter Ravdin, a research professor at M.D.
Decline in Breast Cancer Cases Likely Linked to Reduced Use of ...
(HealthNewsDigest.com).. 12/14/06 In 2003, breast cancer incidence in the United States dropped sharply, and this decline may largely be due to the fact that millions of older women stopped using hormone replacement therapy (HRT) in 2002, according to a new analysis led by researchers at The University of Texas M. D. Anderson Cancer Center. (Photo: Donald Berry, Ph.D) At the 29th annual San Antonio Breast Cancer Symposium, the investigators report that there was an overall 7 percent relative decline in breast cancer incidence between 2002 and 2003, and that the steepest decline - 12% - occurred in women between ages 50-69 diagnosed with estrogen receptor positive (ER-positive) breast cancer. This is the kind of breast cancer that is dependent on hormones for tumor growth. From this, the researchers conclude that as many as 14,000 fewer women were diagnosed with breast cancer in 2003 than in 2002, a year in which the American Cancer Society estimates 203,500 new cases of breast cancer were diagnosed.
Breast cancer scare forces ABC to relocate
Staff at the ABC studios in Brisbane will be moved off site within days after a report found serious concerns about the incidence of breast cancer. An independent panel of experts has found 10 women have developed the disease while working on the site since 1995. The panel's chairman, Professor Bruce Armstrong, says the rate of breast cancer at the Toowong studios is up to 11 times higher than what would normally be expected. Despite extensive testing, the cause has not been found. But Professor Armstrong says it cannot be put down to chance. The ABC's managing director, Mark Scott, says the entire site will be cleared by January. Staff in the news building will leave as soon as today. It is still not certain where they will be relocated to.
Orion Genomics Announces The Discovery And Validation Of Novel ...
Orion Genomics announced today that the company has identified and validated a suite of novel breast cancer biomarkers, the most promising of which will be incorporated into the company's diagnostic assays for the early detection of breast cancer and the detection of breast cancer recurrence. Using proprietary genome-wide microarray technology, the company was able to quickly identify a suite of novel biomarkers in a panel consisting of normal and cancerous breast tissues. In a second independent biomarker validation panel of more than 200 normal and cancerous breast tissues, over 50 biomarkers demonstrated significant diagnostic potential, the most promising of which presented 90 percent sensitivity and 96 percent specificity. The results of Orion's genome-wide, DNA methylation profiling were presented at the 29th Annual San Antonio Breast Cancer Symposium on December 14, 2006 in San Antonio, Texas.
|
